Unlike the DEN-HFD HCC, the MYC;Trp53−/− HCC did not involve the process of fatty liver formation.39 We titrated the dosage of aldometanib and selected 100 mg/L, which did not lead to a significant decrease in body weight in these lean mice before tumor formation, nor did it cause any AMPK-independent effects, as described in our previous study.38 Aldometanib at this dosage also suppressed the development of HCC in the MYC;Trp53−/− mice (Fig. 1e; Supplementary information, Fig. S4a–f). This evidence concerns the gene PRKAA1 and hepatocellular carcinoma.